Septerna: The SEP-479 Readout Could Unlock Further Upside
Stifel Maintains Buy on Septerna, Raises Price Target to $60
What Septerna Shares Profit To Loss Swing Means For Shareholders
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Septerna Q3 EPS $(0.57) Misses $(0.45) Estimate, Sales $18.881M Miss $20.780M Estimate
Guggenheim Maintains Buy on Septerna, Raises Price Target to $65
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $61
Septerna Announces Selection Of SEP-204 As Potential Development Candidate For Treatment Of Graves’ Disease And TED; Reports Initial Preclinical Data Ahead Of Poster Presentation At 2026 ATA Annual Meeting
Septerna to Participate in Upcoming Investor Conferences
Is Septerna (SEPN) Stock Too Rich, Or Still Reasonable?
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
JP Morgan Maintains Overweight on Septerna, Raises Price Target to $48
Jones Trading Maintains Buy on Septerna, Raises Price Target to $62
Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $50
HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $60
Guggenheim Maintains Buy on Septerna, Raises Price Target to $51
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.